产品编号 | BIO0964SM |
英文名称 | Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab Biosimilar) |
中文名称 | |
别 名 | IL-17 / IL-17A / CTLA-8 & IL-17F & Serum Albumin / SA / HSA; Sonelokimab |
抗体来源 | Human |
克隆类型 | |
克 隆 号 | Sonelokimab (Trispecific) |
产品应用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理论分子量 | 40.93 kDa |
检测分子量 | |
性 状 | Lyophilized |
亚 型 | VHH-VHH-VHH |
纯化方法 | Protein A |
缓 冲 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
保存条件 | -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles. |
注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
产品介绍 | |
产品图片 |
Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Sonelokimab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig 3, Sonelokimab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 2.877 nM.
Sonelokimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP) , and read OD450. As shown in fig, Sonelokimab bound in hu-HSA-Fc, and the EC50 was 0.022nM.
Sonelokimab bound to IL-17F protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP) , and read OD450. As shown in fig, Sonelokimab bound in hu-IL-17F-Fc, and the EC50 was 0.009 nM.
The purity of Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) is 98.70%, determined by SEC-HPLC.
Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
1、抗体溶解方法 | |
2、抗体修复方式 | |
3、常用试剂的配制 | |
4、免疫组化操作步骤 | |
5、免疫组化问题解答 | |
6、Western Blotting 操作步骤 | |
7、Western Blotting 问题解答 | |
8、关于肽链的设计 | |
9、多肽的溶解与保存 | |
10、酶标抗体效价测定程序 | |